Market Intelligence, Clinical Progress, and High-Purity Reagents for Immunotherapy and Autoimmune Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for IL27RA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL27RA ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View IL27RA Products |
| Gene Delivery | IL27RA Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IL27RA Products |
| Benchmark Ab | Anti-IL27RA Recombinant Antibody Recombinant positive control. |
View IL27RA Products |
| Validator | IL27RA siRNA Set For knockdown verification. |
View IL27RA Products |
| Related Target A | GP130 Co-receptor subunit required for IL-27 signaling transduction. |
View GP130 Products |
| Related Target B | IL27 Heterodimeric cytokine ligand composed of IL27p28 and EBI3 subunits. |
View IL27 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse evaluation | Human, Mouse, and Cynomolgus IL27RA ortholog proteins available with >95% purity |
| Subfamily counter screening | Homolog panel proteins (gp130, IL12RB1) strictly verified by mass spectrometry |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives | Validated siRNA included for specificity checks |
Live IL27RA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL27RA therapeutics is intensifying, with major players shifting focus from traditional mAbs to targeted combination therapies and bispecific platforms. As first-generation therapies reach the clinic, the next wave of R&&D is targeting the blockade of the IL-27/IL27RA signaling axis to overcome anti-PD-1 resistance in cold tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody | GSK, Surface Oncology | Solid Tumors, Inflammatory Diseases | Ligand Blocking Assay (Need high-purity ECD-Fc proteins) |
| Bispecific Antibody | Emerging Biotechs | Immuno-oncology | Heterodimer Validation (Need Cross-reactive Abs & GP130 proteins) |
| Small Molecule / Inhibitor | Academic Institutes | Autoimmune Disorders | Selectivity Assay (Need Mutant vs WT Recombinant Proteins) |